• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Design, Synthesis, and Characterization of a Fluorescence Polarization Pan-BET Bromodomain Probe.一种荧光偏振泛 BET 溴结构域探针的设计、合成与表征
ACS Med Chem Lett. 2018 Oct 31;9(12):1223-1229. doi: 10.1021/acsmedchemlett.8b00380. eCollection 2018 Dec 13.
2
Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.发现四氢喹喔啉类化合物作为溴结构域和额外末端结构域(BET)抑制剂,对第二个溴结构域具有选择性。
J Med Chem. 2018 May 24;61(10):4317-4334. doi: 10.1021/acs.jmedchem.7b01666. Epub 2018 May 3.
3
Discovery of Benzo[]indol-2(1)-ones and Pyrrolo[4,3,2-]quinolin-2(1)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis.苯并[吲哚-2(1H)-酮]和吡咯并[4,3,2-de]喹啉-2(1H)-酮作为溴结构域和额外末端结构域(BET)抑制剂的发现,对第一个溴结构域具有选择性,对急性痛风性关节炎具有潜在的高效性。
J Med Chem. 2019 Dec 26;62(24):11080-11107. doi: 10.1021/acs.jmedchem.9b01010. Epub 2019 Dec 13.
4
Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit.从 DNA 编码文库技术筛选命中物中发现高选择性 BET BD2 抑制剂。
J Med Chem. 2021 Aug 12;64(15):10806-10833. doi: 10.1021/acs.jmedchem.1c00412. Epub 2021 Jul 12.
5
Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate.设计、合成和表征 I-BET567,一种泛溴结构域和末端(BET)溴结构域口服候选药物。
J Med Chem. 2022 Feb 10;65(3):2262-2287. doi: 10.1021/acs.jmedchem.1c01747. Epub 2022 Jan 7.
6
Binding Assays for Bromodomain Proteins: Their Utility in Drug Discovery in Oncology and Inflammatory Disease.溴结构域蛋白的结合测定:它们在肿瘤学和炎症性疾病药物发现中的应用。
Curr Protoc Pharmacol. 2018 Mar;80(1):3.16.1-3.16.14. doi: 10.1002/cpph.35.
7
Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.新型 4-苯基异喹啉酮 BET 溴结构域抑制剂的设计、合成与生物评价。
Bioorg Med Chem Lett. 2018 Jun 1;28(10):1811-1816. doi: 10.1016/j.bmcl.2018.04.016. Epub 2018 Apr 10.
8
Progress in the Development of non-BET Bromodomain Chemical Probes.非BET溴结构域化学探针的研发进展
ChemMedChem. 2016 Mar 4;11(5):477-87. doi: 10.1002/cmdc.201500540. Epub 2016 Jan 8.
9
Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.探索对人类溴结构域与额外末端结构域(BET)蛋白首个溴结构域的选择性抑制作用。
J Med Chem. 2016 Feb 25;59(4):1634-41. doi: 10.1021/acs.jmedchem.5b01708. Epub 2016 Jan 6.
10
Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.新型小分子诱导的溴结构域和末端(BET)溴结构域蛋白 BRD4 和 BRD2 选择性降解的发现及其细胞效力。
Bioorg Med Chem. 2020 Jan 1;28(1):115181. doi: 10.1016/j.bmc.2019.115181. Epub 2019 Nov 11.

引用本文的文献

1
Macrocyclic dihydropyridine analogs as pan-BET BD2-preferred inhibitors.作为泛BET BD2优先抑制剂的大环二氢吡啶类似物。
Eur J Med Chem. 2025 Jun 5;290:117504. doi: 10.1016/j.ejmech.2025.117504. Epub 2025 Mar 16.
2
Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity.双价 BET 溴结构域抑制剂通过蛋白质构象可塑性赋予 BRDT 更高的效力和选择性。
J Med Chem. 2022 Aug 11;65(15):10441-10458. doi: 10.1021/acs.jmedchem.2c00453. Epub 2022 Jul 22.
3
Quantifying the Selectivity of Protein-Protein and Small Molecule Interactions with Fluorinated Tandem Bromodomain Reader Proteins.量化氟代串联溴结构域读蛋白与蛋白质-蛋白质和小分子相互作用的选择性。
ACS Chem Biol. 2020 Nov 20;15(11):3038-3049. doi: 10.1021/acschembio.0c00720. Epub 2020 Nov 3.

本文引用的文献

1
Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.利用水网络实现焓驱动的、溴结构域选择性的BET抑制剂。
Bioorg Med Chem. 2018 Jan 1;26(1):25-36. doi: 10.1016/j.bmc.2017.10.042. Epub 2017 Nov 4.
2
BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen.通过虚拟筛选发现的一步合成BET溴结构域抑制剂
J Med Chem. 2017 Jun 22;60(12):4805-4817. doi: 10.1021/acs.jmedchem.6b01336. Epub 2017 Jun 7.
3
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.BET 家族溴结构域抑制剂 ABBV-075 的临床前特征提示联合治疗策略。
Cancer Res. 2017 Jun 1;77(11):2976-2989. doi: 10.1158/0008-5472.CAN-16-1793. Epub 2017 Apr 17.
4
Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics.强效双BET溴结构域-激酶抑制剂作为增值多靶点化学探针和癌症治疗药物
Mol Cancer Ther. 2017 Jun;16(6):1054-1067. doi: 10.1158/1535-7163.MCT-16-0568-T. Epub 2017 Mar 23.
5
A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT.一个溴结构域-DNA 相互作用促进 BET 蛋白 BRDT 对乙酰化依赖的双价核小体的识别。
Nat Commun. 2016 Dec 19;7:13855. doi: 10.1038/ncomms13855.
6
Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.溴结构域小分子溴孢菌素可普遍靶向溴结构域,鉴定 BET 蛋白为白血病初级转录反应的主要调控因子。
Sci Adv. 2016 Oct 12;2(10):e1600760. doi: 10.1126/sciadv.1600760. eCollection 2016 Oct.
7
Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.4,5-二氢苯二氮䓬酮衍生物作为新型BRD4抑制剂化学系列的开发。
Eur J Med Chem. 2016 Oct 4;121:294-299. doi: 10.1016/j.ejmech.2016.05.057. Epub 2016 May 27.
8
NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds.用于筛选靶向BRD4化合物的基于核磁共振的片段药物发现平台。
Acta Pharmacol Sin. 2016 Jul;37(7):984-93. doi: 10.1038/aps.2016.19. Epub 2016 May 30.
9
Dual Screening of BPTF and Brd4 Using Protein-Observed Fluorine NMR Uncovers New Bromodomain Probe Molecules.利用蛋白质观测氟核磁共振对BPTF和Brd4进行双重筛选,发现新型溴结构域探针分子。
ACS Chem Biol. 2015 Oct 16;10(10):2246-56. doi: 10.1021/acschembio.5b00483. Epub 2015 Jul 28.
10
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.基于片段的2-噻唑烷酮类BRD4抑制剂药物发现:2. 基于结构的优化。
J Med Chem. 2015 Feb 12;58(3):1281-97. doi: 10.1021/jm501504k. Epub 2015 Jan 14.

一种荧光偏振泛 BET 溴结构域探针的设计、合成与表征

Design, Synthesis, and Characterization of a Fluorescence Polarization Pan-BET Bromodomain Probe.

作者信息

Paulson Carolyn N, Guan Xianghong, Ayoub Alex M, Chan Alice, Karim Rezaul M, Pomerantz William C K, Schönbrunn Ernst, Georg Gunda I, Hawkinson Jon E

机构信息

Department of Medicinal Chemistry and Institute for Therapeutics Discovery & Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.

Department of Chemistry, University of Minnesota, 207 Pleasant Street, SE, Minneapolis, Minnesota 55455, United States.

出版信息

ACS Med Chem Lett. 2018 Oct 31;9(12):1223-1229. doi: 10.1021/acsmedchemlett.8b00380. eCollection 2018 Dec 13.

DOI:10.1021/acsmedchemlett.8b00380
PMID:30613330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6295860/
Abstract

Several chemical probes have been developed for use in fluorescence polarization screening assays to aid in drug discovery for the bromodomain and extra-terminal domain (BET) proteins. However, few of those have been characterized in the literature. We have designed, synthesized, and thoroughly characterized a novel fluorescence polarization pan-BET chemical probe suitable for high-throughput screening, structure-activity relationships, and hit-to-lead potency and selectivity assays to identify and characterize BET bromodomain inhibitors.

摘要

已经开发了几种化学探针用于荧光偏振筛选测定,以辅助针对溴结构域和额外末端结构域(BET)蛋白的药物发现。然而,其中很少有在文献中得到表征。我们设计、合成并全面表征了一种新型的荧光偏振泛BET化学探针,适用于高通量筛选、构效关系研究以及从苗头化合物到先导化合物的效力和选择性测定,以鉴定和表征BET溴结构域抑制剂。